Jeito Capital Achieves Record Fund Close
Jeito Capital, an independent European private equity firm specializing in biopharma investments, has closed its second fund, Jeito II, at €1bn ($1.2bn), according to Private Equity Wire. This closing triples the firm’s assets under management to €1.6bn and marks the largest raise ever by a fully independent European biopharma fund. Jeito II will back 15–20 clinical-stage biopharma companies addressing severe diseases with high unmet medical needs.
Fund Investment Approach
Jeito II plans to increase the average investment per company to around €150m to accelerate clinical development, market access, and commercial potential. The fund will deploy capital across therapeutic areas including oncology, autoimmune diseases, neurology, cardio-metabolic conditions, obesity, and reproductive medicine. It leverages a multidisciplinary team of over 30 experts in drug development, regulatory affairs, intellectual property, commercial operations, and market access to provide portfolio companies with strategic guidance alongside capital.
Proven Track Record
Jeito’s patient-driven methodology has delivered tangible results, as seen in previous investments. For instance, the firm’s investments in EyeBio and Hi-Bio resulted in successful exits through acquisitions by Merck & Co and Biogen, generating combined upfront payments of nearly $2.5bn with average holding periods of 24 months. According to Private Equity Wire, these outcomes demonstrate the firm’s approach in creating long-term value for patients and investors.
Investor Support
The fund attracted strong support from top-tier institutional and private investors across Europe, North America, and Asia, including sovereign and public funds, pharmaceutical companies, insurance groups, pension funds, family offices, and banks. This broad investor base underscores the appeal of Jeito’s strategy in the biopharma sector, as noted in the source material.
